Skip to Content

  • Search

View Additional Section Content

CC-5013-CLL-002 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-GroupStudy of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial).

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/record/NCT00774345?term=nct00774345&rank=1

Principal Investigator(s)
Willard G. Andrews III, MD

Clinical Trial Categories

  • Leukemia
Contact
The Rosenfeld Cancer Center at 215-481-2402

Location

  • The Rosenfeld Cancer Center

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a
Test

215-481-EXAM

Clinical Trials Details